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The proliferation of herbal-based male sexual performance products, particularly 
those adulterated with phosphodiesterase 5 (PDE5) inhibitors, has sparked grave 
public health and food safety concerns. The advent of their unapproved 
analogues presents an additional challenge to forensic drug testing laboratories, 
as these adulterants may evade detection during routine screening. A 
comprehensive strategy is warranted to address these problems and protect 
consumers’ health and well-being. This study investigated the presence of PDE5 
inhibitors as adulterants in herbal remedies, using a two-tier screening strategy 
of rapid qualitative assay and confirmatory analytical analysis. 
 
A bioactivity-based PDE5 inhibition assay was established using fluorescein-
labelled cyclic-3’,5’-guanosine monophosphate as substrates to PDE5 enzyme. 
The PDE5 inhibitions, measured using a fluorescence polarisation technique, 
was applied to 50 herbal-based food samples. The results were in agreement 
with the confirmatory analytical analysis for all food products, except for the 
instant coffee premix samples, postulated due to the presence of caffeine. The 
assay, nevertheless, exhibited a promising potential to rapidly screen PDE5 
inhibitors in various types of food products, except those containing naturally-






A confirmatory liquid chromatography-high-resolution mass spectrometry 
(LC-HRMS) analysis was developed using 23 target analytes; selected to 
represent different groups of PDE5 inhibitors, based on their structural 
similarities. The targeted analysis was primarily optimised to mitigate the matrix 
effect (ME), via chromatographic separation, sample extraction, and sample 
dilution. The insignificant ME percentages, within -9.2%–8.8% for all target 
analytes in food and pharmaceutical matrices, were evidenced with satisfactory 
validation results; notably, the accuracy was within 77.4%–124.7%. The 
development, optimisation, and validation of the targeted analysis provided a 
solid foundation for suspected-target and non-targeted screenings. The 
suspected-target screening employed a library comprising 95 PDE5 inhibitors, 
providing extended coverage of known analytes. Contrarily, the non-targeted 
screening adopted top-down and bottom-up approaches to flag novel PDE5 
inhibitors analogues based on common fragmentation patterns of target analytes. 
 
The confirmatory LC-HRMS analysis was applied to 50 herbal-based food 
samples and 52 herbal-based pharmaceutical samples. The targeted analysis 
and the suspected-target screening identified 11 target analytes and detected five 
suspected analytes, respectively, from 74 adulterated samples. The non-targeted 
screening returned insignificant signals, indicating the absence of potentially 
novel analogues. Some of these samples contained up to five different PDE5 
inhibitors and quantified at supratherapeutic level, making them unsafe for 
consumption. The comprehensive strategies provide a superior approach to curb 
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